8-K: Century Therapeutics Reports Q2 2025, Extends Runway

Century Therapeutics announced its second quarter 2025 financial results, provided a business update, and extended its cash runway into Q4 2027, alongside leadership changes.

Summary

• Reported second quarter ended June 30, 2025, financial results.
• Cash runway extended into the fourth quarter of 2027 due to a workforce reduction in July 2025 and prioritization of pipeline development activities.
• Patient dosing is ongoing in the CALiPSO-1 trial for CNTY-101 in B-cell-mediated autoimmune diseases, with two patients dosed and six U.S. and two European sites activated.
• Clinical data for CNTY-101 is on track to be reported by year-end 2025.
• CNTY-308, a CAR-iT cell therapy, is now in IND-enabling studies for B-cell-mediated diseases, with clinical progression expected in 2026.
• CEO Brent Pfeiffenberger, Pharm.D., was appointed Chairman of the Board, succeeding Joseph Jimenez, effective August 14, 2025.
• Joseph Jimenez and Cynthia Butitta stepped down from the Board, effective August 14, 2025, reducing the Board size from eight to six members.
• Kimberly Blackwell was appointed chair of the Nominating and Corporate Governance Committee, and Alessandro Riva was appointed a member of the Compensation Committee.
• A consulting agreement was approved for Joseph Jimenez, allowing his outstanding equity awards to continue vesting for his advisory services.
• Brent Pfeiffenberger received a retention grant of 1,587,614 restricted stock units, vesting 50% on the second anniversary and 50% on the third anniversary of the August 14, 2025, grant date.

Sentiment

Score: 7

Explanation: The company demonstrated strong progress in its clinical and preclinical pipeline, extended its cash runway significantly, and made strategic leadership changes. While net loss increased slightly, the overall operational and strategic updates are positive for future value creation, despite the workforce reduction.

Positives

• Cash runway extended into the fourth quarter of 2027, providing longer financial stability.
• CALiPSO-1 trial for CNTY-101 is progressing with patient enrollment and clinical site activations (six U.S., two Europe).
• On track to report clinical data for CNTY-101 by year-end 2025.
• CNTY-308 is advancing into IND-enabling studies, with clinical studies anticipated in 2026.
• Rapid progress made towards drug candidacy for the first non-immune cell therapy program.
• Preclinical data for CNTY-101 and CNTY-308/Allo-Evasion 5.0 presented at EULAR 2025 Congress showed promising results for B-cell depletion and immune evasion.
• Favorable initial safety and tolerability profile observed for CNTY-101 in the ELiPSE-1 study, with no dose-limiting toxicities (DLTs) or graft-versus-host disease (GvHD) events.
• CNTY-101 demonstrated deep B-cell depletion and trafficking to lymph nodes in ELiPSE-1.
• CNTY-308 shows functional characteristics similar to primary CAR-T cells in preclinical studies, including self-supporting IL-2 secretion, high functional persistence, and complete tumor control.

Negatives

• Net loss increased to $32.5 million for the three months ended June 30, 2025, compared to $31.2 million for the same period in 2024.
• Cash, cash equivalents, and marketable securities decreased to $158.5 million as of June 30, 2025, from $220.1 million as of December 31, 2024.
• The extension of the cash runway was partly achieved through a workforce reduction in July 2025.

Risks

• Ability to successfully advance current and future product candidates through development activities, preclinical studies, and clinical trials.
• Dependence on the success of the lead product candidate, CNTY-101.
• Ability to progress CNTY-101 through clinical development and meet development milestones on anticipated timelines.
• Uncertainties inherent in the results of preliminary data, pre-clinical studies, and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials.
• Ability to obtain clearance of future Investigational New Drug (IND) or Clinical Trial Application (CTA) submissions and commence and complete clinical trials on expected timelines, or at all.
• Reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of product candidates.
• The timing, scope, and likelihood of regulatory filings and approvals, including final regulatory approval of product candidates.
• Impact of geopolitical issues, trade disputes and tariffs, banking instability, and inflation on business and operations, supply chain, and labor force.
• Performance of third parties in connection with the development of product candidates, including third parties conducting clinical trials as well as third-party suppliers and manufacturers.
• Ability to successfully commercialize product candidates and develop sales and marketing capabilities, if product candidates are approved.
• Ability to recruit and maintain key members of management and maintain and successfully enforce adequate intellectual property protection.

Future Outlook

The company remains on track to report clinical data for CNTY-101 by the end of 2025. Following successful completion of IND-enabling studies and regulatory approval, Century plans to initiate clinical studies for CNTY-308 in 2026. The cash runway is estimated to support operations into the fourth quarter of 2027.

Management Comments

• "In the first half of 2025, we made important business decisions to ensure our capital resource allocation and pipeline development activities are centered on potentially transformational cell therapy candidates and technologies." Brent Pfeiffenberger, CEO.
• "We are pleased by recent progress across our core pipeline, including continued clinical execution of CNTY-101 in autoimmune disease and the acceleration of our core preclinical programs." Brent Pfeiffenberger, CEO.
• "IND-enabling studies are now underway for CNTY-308 and we have made rapid progress toward drug candidacy for our non-immune cell program." Brent Pfeiffenberger, CEO.
• "We will continue to shape the organization as needed and look forward to moving with urgency throughout the remainder of 2025 to deliver clinical data for CNTY-101 and bring our pipeline underpinned by Allo-Evasion 5.0 technology closer to patients." Brent Pfeiffenberger, CEO.
• "As part of this evolution, I am honored to deepen my role in driving the growth and success of Century by assuming the role of Board Chair." Brent Pfeiffenberger, CEO.
• "I wish to extend my heartfelt thanks to Joe for his service as Board Chair over the last four years. He has made a lasting impact on our organization, and I'm pleased to have him continue as a special advisor to the company moving forward." Brent Pfeiffenberger, CEO.
• "It has been a privilege to serve as Century's Board Chair for the last four years. Since Brent assumed the role of CEO, I had the opportunity to see how he has transformed the company, executing strategic deals, fundraising and evolving the pipeline. I am confident his expanded leadership role will create value and drive long-term success as the company seeks to bring much needed therapeutic innovation closer to patients with autoimmune diseases and cancer." Joseph Jimenez.
• "I look forward to following Century's continued development progress across its core programs and supporting through my new role as a special advisor." Joseph Jimenez.

Industry Context

Century Therapeutics operates in the highly competitive and rapidly evolving biotechnology sector, specifically in iPSC-derived cell therapies for autoimmune diseases and cancer. The focus on 'off-the-shelf' allogeneic therapies with Allo-Evasion technology aims to address significant unmet needs in patient access, manufacturing consistency, and re-dosing capabilities, differentiating it from current autologous CAR-T therapies which face challenges in logistics, product availability, and cost. The company's efforts align with the broader industry trend of developing more accessible and scalable cell therapy solutions.

Comparison to Industry Standards

• Current CAR-T cell therapies (e.g., CARVYKTI, ABECMA, YESCARTA, BREYANZI, KYMRIAH, TECARTUS) are patient-derived (autologous) and represented approximately $4.5 billion in worldwide sales in 2024.
• Fewer than 30% of patients eligible for CAR-T cell therapy currently receive it, highlighting a significant access challenge that Century's off-the-shelf allogeneic approach aims to overcome.
• CNTY-308, an iPSC-derived CAR-iT cell, is designed to recapitulate the characteristics of primary CAR-T cells, offering potential for improved time-to-treatment, reliable manufacturing, and reduced cost of goods compared to autologous products.
• The Allo-Evasion technology aims to provide durable responses by enabling repeat dosing, a key differentiator from many existing cell therapies that face host immune rejection.
• Preclinical data for CNTY-101 showed greater potency in eliminating B-cells compared to primary CAR-T cells from healthy donors in a 24-hour in vitro cytolysis study.
• CNTY-308 in preclinical studies demonstrated self-supported IL-2 secretion, high functional persistence (killing for >10 rounds, persisting in blood for 32+ days), and tumor control after rechallenge, comparable to primary CAR-T cells.

Management Changes

Corporate Governance

Related Party Transactions

• A consulting agreement was approved with Joseph Jimenez, a former Board Chair and current special advisor, allowing his outstanding equity awards to continue vesting for his strategic advisory services.

Stakeholder Impact

• Shareholders: Potential positive impact from extended cash runway, pipeline progress, and strategic leadership changes. The retention award for the CEO aligns his interests with long-term company performance.
• Employees: A workforce reduction was completed in July 2025, impacting some employees, but the remaining team is focused on prioritized programs.
• Patients: Continued progress in clinical trials (CNTY-101) and preclinical development (CNTY-308, non-immune cell program) offers hope for future therapeutic options in autoimmune diseases and cancer.
• Management: CEO Brent Pfeiffenberger's expanded role as Board Chair and retention award indicate strong confidence and commitment from the Board.

Next Steps

• Continue patient enrollment and clinical trial site activations for the CALiPSO-1 trial.
• Report clinical data for CNTY-101 by the end of 2025.
• Initiate initial patient enrollment and dosing in the CARAMEL IIT study in Q3 2025.
• Complete IND-enabling studies for CNTY-308.
• Initiate clinical studies for CNTY-308 in 2026, pending regulatory approval.
• Continue accelerating preclinical development of the non-immune cell program towards drug candidacy.
• Continue to shape the organization as needed to optimize resource allocation.

Key Dates

Recommendation

While Century Therapeutics has demonstrated significant progress in its clinical pipeline, extended its cash runway, and made strategic leadership appointments, the company continues to operate at a net loss. The positive developments, such as the advancement of CNTY-101 and CNTY-308, are promising but still in early to mid-stage development, carrying inherent risks. The extension of the cash runway, while crucial, was partly achieved through a workforce reduction, indicating ongoing cost management efforts. Investors should hold to monitor the upcoming clinical data for CNTY-101 by year-end 2025 and the progression of CNTY-308 into clinical studies in 2026, as these milestones will be critical determinants of future value.

Keywords

Century Therapeutics, IPSC, Cell Therapy, Autoimmune Disease, Cancer, CNTY-101, CNTY-308, Allo-Evasion, Clinical Trials, Financial Results, Biotechnology, CAR-iNK, CAR-iT, SEC Filing, Corporate Governance, Cash Runway